Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome.

Brown PM, Drossman DA, Wood AJ, Cline GA, Frazier KS, Jackson JI, Bronner J, Freiman J, Zambrowicz B, Sands A, Gershon MD.

Gastroenterology. 2011 Aug;141(2):507-16. doi: 10.1053/j.gastro.2011.05.005. Epub 2011 May 18.

2.

LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin.

Camilleri M.

Neurogastroenterol Motil. 2011 Mar;23(3):193-200. doi: 10.1111/j.1365-2982.2010.01643.x. Epub 2010 Dec 15. Review.

4.

Targeting serotonin synthesis to treat irritable bowel syndrome.

Tack J, Janssen P, Wouters M, Boeckxstaens G.

Gastroenterology. 2011 Aug;141(2):420-2. doi: 10.1053/j.gastro.2011.06.024. Epub 2011 Jun 22. No abstract available.

PMID:
21703266
5.

Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.

Dove LS, Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, McIntyre G, Almenoff JS, Covington PS.

Gastroenterology. 2013 Aug;145(2):329-38.e1. doi: 10.1053/j.gastro.2013.04.006. Epub 2013 Apr 9.

6.

Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.

Fukudo S, Ida M, Akiho H, Nakashima Y, Matsueda K.

Clin Gastroenterol Hepatol. 2014 Jun;12(6):953-9.e4. doi: 10.1016/j.cgh.2013.11.024. Epub 2013 Dec 4.

7.

Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.

Rivkin A, Rybalov S.

Pharmacotherapy. 2016 Mar;36(3):300-16. doi: 10.1002/phar.1712. Epub 2016 Mar 11. Review.

PMID:
26971716
8.

Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of Constipation-predominant Irritable Bowel Syndrome: A Randomized Controlled Trial.

Bensoussan A, Kellow JE, Bourchier SJ, Fahey P, Shim L, Malcolm A, Boyce P.

Clin Gastroenterol Hepatol. 2015 Nov;13(11):1946-54.e1. doi: 10.1016/j.cgh.2015.06.022. Epub 2015 Jun 29.

PMID:
26133902
9.

Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.

Andresen V, Montori VM, Keller J, West CP, Layer P, Camilleri M.

Clin Gastroenterol Hepatol. 2008 May;6(5):545-55. doi: 10.1016/j.cgh.2007.12.015. Epub 2008 Jan 31. Review.

10.

Eluxadoline for Irritable Bowel Syndrome with Diarrhea.

Lembo AJ, Lacy BE, Zuckerman MJ, Schey R, Dove LS, Andrae DA, Davenport JM, McIntyre G, Lopez R, Turner L, Covington PS.

N Engl J Med. 2016 Jan 21;374(3):242-53. doi: 10.1056/NEJMoa1505180.

11.

Comparison of 5-hydroxytryptophan signaling pathway characteristics in diarrhea-predominant irritable bowel syndrome and ulcerative colitis.

Yu FY, Huang SG, Zhang HY, Ye H, Chi HG, Zou Y, Lv RX, Zheng XB.

World J Gastroenterol. 2016 Mar 28;22(12):3451-9. doi: 10.3748/wjg.v22.i12.3451.

12.

Rifaximin therapy for patients with irritable bowel syndrome without constipation.

Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP; TARGET Study Group..

N Engl J Med. 2011 Jan 6;364(1):22-32. doi: 10.1056/NEJMoa1004409.

13.

A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.

Rao S, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, Shi K, MacDougall JE, Shao JZ, Eng P, Fox SM, Schneier HA, Kurtz CB, Johnston JM.

Am J Gastroenterol. 2012 Nov;107(11):1714-24; quiz p.1725.

14.

Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial.

Choi CH, Kwon JG, Kim SK, Myung SJ, Park KS, Sohn CI, Rhee PL, Lee KJ, Lee OY, Jung HK, Jee SR, Jeen YT, Choi MG, Choi SC, Huh KC, Park H.

Neurogastroenterol Motil. 2015 May;27(5):705-16. doi: 10.1111/nmo.12544. Epub 2015 Mar 25. Erratum in: Neurogastroenterol Motil. 2015 Nov;27(11):1684-5. Dosage error in article text.

15.

[Serum serotonin concentration and urine 5-hydroxyindole acetic acid excretion in patients with irritable bowel syndrome].

Moskwa A, Chojnacki J, Wiśiewska-Jarosińska M, Stec-Michalska K, Szadkowski K, Smigielski J, Chojnacki C.

Pol Merkur Lekarski. 2007 May;22(131):366-8. Polish.

PMID:
17679369
16.

Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.

Ducrotte P, Dapoigny M, Bonaz B, Siproudhis L.

Aliment Pharmacol Ther. 2005 Feb 15;21(4):435-44.

17.
18.

Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study.

Tack JF, Miner PB Jr, Fischer L, Harris MS.

Aliment Pharmacol Ther. 2011 Oct;34(8):868-77. doi: 10.1111/j.1365-2036.2011.04818.x. Epub 2011 Aug 24.

19.

Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.

Videlock EJ, Cheng V, Cremonini F.

Clin Gastroenterol Hepatol. 2013 Sep;11(9):1084-1092.e3; quiz e68. doi: 10.1016/j.cgh.2013.04.032. Epub 2013 May 2.

PMID:
23644388
20.

Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.

Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, MacDougall JE, Jia XD, Shao JZ, Fitch DA, Baird MJ, Schneier HA, Johnston JM.

Am J Gastroenterol. 2012 Nov;107(11):1702-12.

PMID:
22986437

Supplemental Content

Support Center